生化科技藥品之發展：新技術之分析

Abstract

Research Overview

Advances in Biotechnology Cause an Overhaul of Processes in the Pharmaceuticals Industry

Scientific developments in biotechnology have radically changed the global pharmaceuticals industry, since biopharmaceuticals can be tailored for specific medical problems in different individuals. With biotechnology, any drug can be genetically modified using cell fusion or deoxyribonucleic acid (DNA)-recombinant technologies to alter specificities for individual diseases. Some distinct advantages of biotechnology include fewer side effects and more potent effect on target cells. Pharmaceutical biotechnology is being developed further to fight cancer, viral infections, diabetes, and hepatitis as well as for developing safer and more effective antibiotics, insulins, interferons, estrogens, and human growth hormones.

This Technical Insights study provides an overview of the advances made by emerging technologies in biopharmaceuticals. The study includes detailed analyses of monoclonal antibodies, hormones and enzymes, cytokines and peptide therapeutics, vaccines and antigens, along with tissue engineering. It also provides technology challenges, market drivers and restraints as well as assesses innovations and opportunities. This research service enables companies to align their positioning strategies to benefit from these technologies.

Intense Research and Development Efforts Create a New Class of Biopharmaceuticals

Research organizations have invested vast amounts of resources in innovations in biotechnologies, which has resulted in the commercialization of new classes of biopharmaceuticals that find application in both disease therapy and prevention. Recently, biopharmaceuticals witnessed significant innovations and a robust pipeline of new biotherapeutics indicates strong growth for the biopharmaceutical industry in the short to medium term. Improvements in biotechnologies and sustained successes in the monoclonal antibody segment have enabled scientists to introduce novel categories of biopharmaceuticals that address fresh markets and target new diseases.

In the future, the biopharmaceutical industry is likely to increasingly focus on products and, more particularly, on the diverse potential of monoclonal antibody products," says the analyst of this research service. "Although new technologies are expected to continue to emerge, the spectrum of supportive technologies currently available is now permitting a growing pipeline of novel therapeutics". Biopharmaceutical drugs have already gained approval for use in oncology and inflammatory diseases and are gradually expected to permeate other areas of medical practice.

Advances in Gene Therapy and Genetic Engineering Present Tremendous Opportunities for Biopharmaceuticals

The mapping of the human genome has uncovered numerous new potential disease targets. Gene therapy involves the insertion of genetic materials into cells in order to repair or replace defective genes and to make the target cells more susceptible to treatment. "An understanding of genomics and proteomics, along with biotechnology, has greatly spurred growth of biopharmaceutical technologies," notes the analyst. "The ability to identify the exact genetic sequences to control the production of specific proteins has introduced many biopharmaceuticals for almost all applications.

Biopharmaceuticals greatest potential lies in gene therapy and genetic engineering, which have been revolutionizing medicine with their ability to mass produce safe and more effective versions of proteins and enzymes created naturally by the human body.

Table of Contents

• 1. Executive Summary
  • 1. Introduction
    • 1. Introduction to Biopharmaceuticals
    • 2. Overview of the Biopharmaceutical Industry
  • 2. Scope & Methodology
    • 1. Scope and Segmentation of this Research Service
    • 2. Methodology
• 2. Monoclonal Antibody Technologies
  • 1. Technology Primer
    • 1. An Overview of Monoclonal Antibodies
    • 2. Applications
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Cost-Effective System for Production of Monoclonal Antibodies in Yeast
    • 2. Antibody-Vaccine Combination Therapy for Melanoma
    • 3. Abbotts Fully Human Anti-Il-12 Monoclonal Antibody
    • 4. Monoclonal Antibody for Autoimmune Diseases
    • 5. Anti-IL-9 Monoclonal Antibody for Controlling Asthma
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 3. Vaccines and Antigens
  • 1. Technology Primer
    • 1. An Overview of Vaccines
    • 2. Emerging Applications of Vaccines
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. DNA Sequences for Stimulating Immune Responses
    • 2. Single-Dose AIDS Vaccine in Phase I Trials
    • 3. Prostate Cancer Vaccine in Phase III Trials
    • 4. Novel Cancer Immunotherapy Product for Colorectal Cancer
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 4. Tissue Engineering
  • 1. Technology Primer
    • 1. Overview
    • 2. Applications
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Stem Cell Therapy for Regeneration of Meniscus
    • 2. Advances in Cloning Create Patient-Specific Stem Cells
    • 3. Feeder-Free Derivation of Embryonic Stem Cells
    • 4. Naturally-Derived Extracellular Matrix Material for Wound Management
    • 5. Telomerase Technology for Developing Human Embryonic Stem Cells
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 5. Hormones and Enzymes
  • 1. Technology Primer
    • 1. Human Insulins
    • 2. Human Growth Hormones
    • 3. Tissue Plasminogen Activators
    • 4. Thyroid Stimulating Hormones
    • 5. Fertility Hormones
    • 6. Blood Clotting Factors
    • 7. Recombinant Enzymes
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Recombinant Enzyme for Dissolving Blood Clots
    • 2. Enzyme Replacement Therapy for Mucopolysaccharidosis
    • 3. Natural Plant Enzyme to be a Potential Candidate for Lung Cancer
    • 4. Recombinant Human Thrombin as an Alternative to Bovine-Derived Product
• 6. Cytokines and Peptide Therapeutics
  • 1. Technology Primer
    • 1. Colony Stimulating Factors
    • 2. Interleukins
    • 3. Interferons
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Low Dose Interferon Alpha Provides Effective Treatment for Variety of Conditions
    • 2. Natural Peptide Promotes Wound Healing
    • 3. Discovery of Protein Leads to Potential Pathway for Treating MultiplemSclerosis
    • 4. Recombinant Natriuretic Peptide for Heart Failure
    • 5. Protein as a Marker and Target for Breast Cancer
    • 6. Recombinant Beta Interferon for Multiple Sclerosis
• 7. Technology Adoption Factor Analysis and Commercial Landscape
  • 1. Technology Analysis
    • 1. Technology Accelerators
    • 2. Technology Roadblocks
    • 3. Regulatory Trends
  • 2. Corporate Collaborations
    • 1. Part I
    • 2. Part II
• 8. Database of Key Industry Participants; Selected Patents & Glossary
  • 1. Database of Key Industry Participants
    • 1. Companies and Organizations
    • 2. Universities and Academia
  • 2. Selected Patents & Glossary
    • 1. Important Patents I
    • 2. Important Patents II
• 9. Critical Reference Tables
  • 1. Healthcare Expenditure
    • 1. Government Healthcare Expenditure
    • 2. Private Healthcare Expenditure
  • 2. Biotech Expenditure
    • 1. Number of Biotech Companies (1999-2006)
    • 2. Government Investment in Biotech R&D (1999-2006)
    • 3. Private Investment in Biotech R&D (1999-2006)
  • 3. Number of Biotech Patents
    • 1. USPTO Biotech Patents (1996-2000)
    • 2. EPO Biotech Patents (1996-2000)